Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.
| Website | http://www.hemerion.com |
| Employees | 17 (11 on RocketReach) |
| Founded | 2020 |
| Technologies |
JavaScript
,
HTML
,
PHP
+19 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Glioblastoma, Biotechnology, Brain Cancer, Oncology, Neuro Oncology, Drug Development, Cancer Treatment, Therapeutics, Cancer Research, Clinical Trials, Pharmaceutical, Targeted Therapy, Healthtech, Precision Medicine, Innovative Therapies, Clinical Stage, Immunotherapy, Medical Research, Stem Cells |
| Competitors | Novartis, AstraZeneca, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Biogen, Alnylam Pharmaceuticals, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +39 more (view full list) |
Looking for a particular Hemerion Therapeutics employee's phone or email?
Hemerion Therapeutics Questions
Maximilien Vermandel is the CEO of Hemerion Therapeutics.
11 people are employed at Hemerion Therapeutics.
Hemerion Therapeutics is based in Lille, Hauts-de-France.
Top Hemerion Therapeutics Employees
-
Serge Mordon
Co-Founder Hemerion Therap at Hemerion Therapeutics
Ascain, Nouvelle-Aquitaine, FR -
Michel Andraud
Chief Financial Officer at Hemerion Therapeutics
Caluire-et-Cuire, FR43 -
Marine Gillon
Office Manager at Hemerion Therapeutics
Villeneuve-d'Ascq, FR1 -
Cécile Thévenet
Quality Assurance Manager at Hemerion Therapeutics
Sailly-lez-Lannoy, FR
Related Companies
